MarketRocky Mountain Laboratories
Company Profile

Rocky Mountain Laboratories

Rocky Mountain Laboratories (RML) is part of the NIH Intramural Research Program and is located in Hamilton, Montana. Operated by the National Institute of Allergy and Infectious Diseases, RML conducts research on maximum containment pathogens such as Ebola as well as research on prions and intracellular pathogens such as Coxiella burnetii and Francisella tularensis. RML operates one of the few Biosafety level 4 laboratories in the United States, as well as Biosafety level 3 and ABSL3/4 laboratories.

History
RML evolved as a result of research on Rocky Mountain spotted fever that began around 1900, in the Bitterroot Valley. A deadly disease of unknown origin plagued early settlers of the valley. It was known locally as "black measles" because of its severe, dark rash. Montana researchers were working in the area in makeshift cabins and tents. In 1909, Dr. Howard Taylor Ricketts, while working in the area, isolated Rickettsia rickettsii as the Gram-negative bacterium that causes Rocky Mountain spotted fever. H. R. Cox and Gordon Davis working at RML discovered that Coxiella burnetii was the causative agent of Q fever. During World War II, the United States Public Health Service used the laboratory to manufacture Yellow fever vaccine. When the human serum–base vaccine caused an outbreak of Hepatitis B that infected more than 350,000 U.S. soldiers, two researchers at the laboratory, Dr. Mason Hargett and Harry Burruss, developed an aqueous-base vaccine that combined distilled water with virus grown in chicken eggs. By the end of the war, the laboratory distributed more than 1 million doses of the improved yellow fever vaccine. In the post-war decades, the laboratory broadened its scope to study chlamydia trachomatis and transmissible spongiform encephalopathies including scrapie, mad cow disease, and chronic wasting disease. In 1982, Dr. Willy Burgdorfer discovered Borrelia burgdorferi, the tick-borne bacterium that causes Lyme disease. ==Post 9/11 and BSL-4 Facility==
Post 9/11 and BSL-4 Facility
In the aftermath of September 11 attacks, Dr. Anthony Fauci and others advised President George W. Bush on a national bio-defense program with one element of that program being the construction of a state-of-the-art BSL-4 facility at RML, since the Bethesda campus of NIAID did not have the necessary real estate to build a facility and because of RML's 100-year history of studying zoonotic infectious diseases. The Integrated Research Facility opened in 2008 and has enabled research on emergent tick and mosquito-borne flaviviruses in North America and includes a cryo-electron microscopy facility for the structural study of emergent pathogens. Around 2009, Heinz Feldmann and Vincent Munster relocated to RML. In 2011, RML published its first transmissible vaccine paper for "disseminating" an Ebola vaccine to prevent Ebola transmission in wildlife populations. In 2018, RML won two DARPA projects for transmissible animal vaccines. ==Contributions to Understanding SARS-CoV-2==
Contributions to Understanding SARS-CoV-2
Dr. Vincent Munster and Dr. Michael Letko, beginning in 2016, built new tools to study the mechanisms of cell entry of betacoronaviruses that include MERS-CoV and SARS-CoV.{{Cite web|url=https://videocast.nih.gov/watch=55222 ==References==
tickerdossier.comtickerdossier.substack.com